/

HOWL

Werewolf Therapeutics, Inc.Closed

0.9911+0.01 +0.95%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.00 +0.90%

Open

1.00

Prev close

0.9818

Day range

0.97001.01

52-week range

0.27001.83

Volume

353.19K0.05×

Mkt cap

48.17M

P/E ttm

—

Fwd P/E

-1.68

EPS ttm

-0.7300

Div yield

0.00%

Earnings

Jul 31, 2026

From 52w high

−45.84%

Price Chart

Yahoo Finance · delayed

HOWLOct 13, 2026O 1.0000H 1.0100L 0.9700C 0.9910+0.0090 (+0.92%)Vol 353.20K

SMA 500.8073
SMA 2000.6559

1Y change −39.20% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

HOWL Werewolf Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +7.72%
1 month: +0.92%
3 months: +188.08%
6 months: +7.95%
Year to date: +56.31%
1 year: −39.20%

Valuation & ownership

Market cap: 48.17M
Enterprise value: 26.18M
P/E (ttm): —
Forward P/E: -1.68
PEG ratio: —
Price / book: 2.96
Price / sales (ttm): 2.29
EV / EBITDA: -1.19
EPS (ttm): -0.7300
EPS (forward): -0.5900
Beta (5y monthly): 0.51
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 48.60M
Float: 45.38M
Short % of float: 6.25%
Short ratio (days): 3.03
Held by insiders: 6.62%
Held by institutions: 39.22%
Avg volume (3m): 6.88M
50-day average: 0.7949
200-day average: 0.6542
52-week change: −39.20%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 63.4
vs 50-day SMA: +22.75%
vs 200-day SMA: +51.10%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.95%
Realised vol (20d, ann.): 50.4%
From 52-week high: −45.85%
From 52-week low: +267.04%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

7.00

+606.29% implied

Low 4.00Median 7.00High 10.00

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 21.00M

DES

About Werewolf Therapeutics, Inc.

Yahoo Finance profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 39
Headquarters: Watertown, MA, United States
Website: werewolftx.com
Officers: Dr. Daniel J. Hicklin Ph.D.

SEAS

Seasonality · HOWL

2021–2026 · monthly returns

Strongest month Jan +20.53%Weakest month Mar −19.10%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.4	-9.4	38.8	-13.6	-37.5	-20.0	-1.9	166.6	-2.0	7.5			+56.3%
2025	-9.5	-7.5	-21.6	-7.2	34.1	-9.9	11.0	8.3	50.4	-33.5	-23.7	-36.6	−57.2%
2024	19.9	49.5	-6.4	-3.7	-17.1	-52.8	-7.8	-4.0	-1.9	20.5	-21.7	-26.0	−61.7%
2023	95.1	-27.9	-9.9	-8.8	34.6	-4.4	-11.8	1.9	-21.9	16.8	-2.0	57.6	+88.3%
2022	-23.5	-21.4	-38.5	1.1	-14.8	7.9	11.5	11.0	-10.9	-34.4	-38.2	12.0	−82.8%
2021					-7.6	17.2	-0.1	2.2	-3.6	-8.7	-7.5	-17.8	−26.0%

INSD

Insider Activity · HOWL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 6, 2026	Evnin Luke BasilDirector	Sale at price 0.31 - 0.32 per share.	143.2K	$44.75K
Jun 28, 2026	Evnin Luke BasilDirector	Sale at price 0.30 per share.	157.1K	$47.13K
Jun 16, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 0.35 per share.	416.9K	$145.92K
Jun 15, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 0.37 - 0.40 per share.	448.8K	$173.76K
Jun 10, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 0.37 - 0.38 per share.	678.2K	$253.57K
Jun 8, 2026	Evnin Luke BasilDirector	Sale at price 0.37 per share.	76.9K	$28.46K
Jun 7, 2026	Evnin Luke BasilDirector	Sale at price 0.40 - 0.44 per share.	105.6K	$43.03K
Jun 2, 2026	Evnin Luke BasilDirector	Sale at price 0.42 - 0.47 per share.	139.8K	$63.63K
May 28, 2026	Evnin Luke BasilDirector	Sale at price 0.45 - 0.48 per share.	141.1K	$66.20K
May 25, 2026	Evnin Luke BasilDirector	Sale at price 0.42 - 0.47 per share.	191.8K	$86.56K
May 19, 2026	Evnin Luke BasilDirector	Sale at price 0.43 - 0.50 per share.	171K	$76.36K
May 12, 2026	Evnin Luke BasilDirector	Sale at price 0.54 per share.	44.7K	$24.13K
May 11, 2026	Evnin Luke BasilDirector	Sale at price 0.64 - 0.70 per share.	407.6K	$280.21K
May 11, 2026	Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 0.64 - 0.71 per share.	565.2K	$390.69K
May 6, 2026	Evnin Luke BasilDirector	Sale at price 0.63 - 0.69 per share.	100.6K	$64.22K
May 3, 2026	Evnin Luke BasilDirector	Sale at price 0.72 - 0.73 per share.	274.6K	$198.31K
Apr 28, 2026	Evnin Luke BasilDirector	Sale at price 0.69 - 0.85 per share.	205.9K	$154.53K
Jan 15, 2026	Evnin Luke BasilDirector	Sale at price 0.54 per share.	38.8K	$20.94K
Jan 14, 2026	Evnin Luke BasilDirector	Sale at price 0.55 - 0.57 per share.	111.2K	$61.79K
Jan 11, 2026	Evnin Luke BasilDirector	Sale at price 0.57 - 0.63 per share.	91.4K	$53.53K

13F

Investors Holding HOWL

latest 13F filings of 29 followed managers

Investors holding HOWL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$242.8K	0.00%	674.63K	+31%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

HOWL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

HOWL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Werewolf Therapeutics, Inc.

Seasonality · HOWL

Insider Activity · HOWL

Congress Trades · HOWL

Investors Holding HOWL

Investors Holding HOWL

Congress Trades · HOWL

Insider Activity · HOWL

Seasonality · HOWL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Werewolf Therapeutics, Inc.

Earnings & Dividends

News